Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.3063 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 Next >
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
From CytoDyn
Via Business Wire
Group of CytoDyn Stockholders Responds to Highly Misleading Company Release
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation
From CytoDyn Inc.
Via Business Wire
CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest
From CytoDyn Inc.
Via Business Wire
CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
From CytoDyn Inc.
Via Business Wire
CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid
From CytoDyn Inc.
Via Business Wire
CytoDyn Inc. (OTC: CYDY) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 07/28/2021 -- An investigation on behalf of current long term investors in CytoDyn Inc. (OTC: CYDY) shares over possible breaches of fiduciary duty by certain officers and... 
Via SBWire
Topics Lawsuit
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities
Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility... 
Via Benzinga
Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
What's Behind This Wild-Card Coronavirus Stock?
Failure is not an option for this small-cap biotech developing a COVID-19 treatment. 
Via The Motley Fool
CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines
After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140... 
Via Benzinga
CytoDyn Stock Falls After FDA Rebukes Claims On COVID-19 Treatment
The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is... 
Via Benzinga
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against CytoDyn, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)
From The Law Offices of Frank R. Cruz
Via Business Wire
MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
These OTC Securities Had the Most Trading Activity in April
April was another fascinating month in OTC Markets trading, as cryptocurrency, internatio... 
Via Benzinga
MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY
From The Rosen Law Firm, P.A.
Via Business Wire
CytoDyn Inc. (OTC:CYDY) Investor Notice: Lawsuit Alleges Misleading Statements by CytoDyn Inc
San Diego, CA -- (SBWIRE) -- 04/27/2021 -- An investor, who purchased shares of CytoDyn Inc. (OTC:CYDY), filed a lawsuit against CytoDyn Inc over alleged violations of Federal Securities Laws. 
Via SBWire
Topics Lawsuit
CYDY Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Encourages Shareholders to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Shareholder Alert: Robbins LLP Announces that CytoDyn Inc. (CYDY) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today
Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.... 
Via Benzinga
Scott+Scott Attorneys at Law LLP Alerts Investors with Losses Over $250,000 to Securities Class Action Against CytoDyn, Inc. (CYDY)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.